Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Bad
|
Filing tables
Filing exhibits
- 10-K Annual report
- 10.7 EX-10.7 Form of Stock Option Terms for 2017 Annual Non-qualified Option Grants
- 10.8 EX-10.8 Form of Stock Option Terms for 2019 Annual Non-qualified Option Grants
- 10.13 EX-10.13 Merck & Co., Inc. U.S. Separation Benefits Plan
- 10.21 EX-10.21 2020 Annual Nqso Terms and Conditions
- 10.22 EX-10.22 2020 Annual Rsu Terms and Conditions
- 10.23 EX-10.23 2021 Annual Psu Terms and Conditions
- 10.24 EX-10.24 2021 Rsu Grant Terms Under Merck Co Inc 2019 Isp
- 10.25 EX-10.25 2022 Annual Rsu Terms and Conditions
- 10.26 EX-10.26 2022 Annual Psu Terms and Conditions August (Guindo)
- 10.27 EX-10.27 2023 Annual Nqso Terms and Conditions
- 10.28 EX-10.28 2022 Annual Psu Terms and Conditions
- 10.29 EX-10.29 2023 Annual Psu Terms and Conditions
- 10.30 EX-10.30 Offer Letter (Guindo)
- 21 EX-21 Subsidiary List
- 23 EX-23 Consent of Independent Registered Public Accounting Firm
- 24.1 EX-24.1 Power of Attorney
- 24.2 EX-24.2 Certification of Board Resolution
- 31.1 EX-31.1 Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 EX-31.2 Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 EX-32.1 Section 1350 Certification of CEO
- 32.2 EX-32.2 Section 1350 Certification of CFO
- 97 EX-97 Merck Recoupment Policy
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links
Exhibit 24.1
POWER OF ATTORNEY
Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2023 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith.
IN WITNESS WHEREOF, this instrument has been duly executed as of the 26th day of February 2024.
MERCK & CO., Inc.
/s/ Robert M. Davis | Chairman, Chief Executive Officer and President | |||||||
Robert M. Davis | (Principal Executive Officer; Director) | |||||||
/s/ Caroline Litchfield | Executive Vice President and Chief Financial Officer | |||||||
Caroline Litchfield | (Principal Financial Officer) | |||||||
/s/ Dalton Smart | Senior Vice President Finance—Global Controller | |||||||
Dalton Smart | (Principal Accounting Officer) |
DIRECTORS
/s/ Douglas M. Baker, Jr. | /s/ Paul B. Rothman | |||||||
Douglas M. Baker, Jr. | Paul B. Rothman | |||||||
/s/ Mary Ellen Coe | /s/ Patricia F. Russo | |||||||
Mary Ellen Coe | Patricia F. Russo | |||||||
/s/ Pamela J. Craig | /s/ Christine E. Seidman | |||||||
Pamela J. Craig | Christine E. Seidman | |||||||
/s/ Thomas H. Glocer | /s/ Inge G. Thulin | |||||||
Thomas H. Glocer | Inge G. Thulin | |||||||
/s/ Risa J. Lavizzo-Mourey | /s/ Kathy J. Warden | |||||||
Risa J. Lavizzo-Mourey | Kathy J. Warden | |||||||
/s/ Stephen L. Mayo | /s/ Peter C. Wendell | |||||||
Stephen L. Mayo | Peter C. Wendell |